Bat virome

Sonoma Pharmaceuticals and Microderm Technologies Announce that Dermodacyn® Disinfecting Solution is Now Available in Hong Kong and Thailand

Retrieved on: 
Thursday, January 28, 2021
Health, Other Health, Surgery, Optical, Other Science, Practice Management, Research, Managed care, Infectious diseases, General Health, Hospitals, Science, Nursing, Medical Supplies, Health, Medicine, Bactericides, Disinfectant, Hygiene, Bat virome, Zoonoses, Severe acute respiratory syndrome, Coronavirus, Virus

Dermodacyn disinfecting solution is designed to be sprayed as an aerosol to disinfect areas suspected to contain bacteria and viruses that can lead to disease.

Key Points: 
  • Dermodacyn disinfecting solution is designed to be sprayed as an aerosol to disinfect areas suspected to contain bacteria and viruses that can lead to disease.
  • Dermodacyn disinfectant is medical grade and can be used in hospitals to keep doctors and patients protected and safe.
  • In a study by the University of Hong Kong and Queen Mary Hospital Dermodacyn disinfecting solution showed it effectively kills the coronavirus SARS-CoV-2.
  • Sonoma Pharmaceuticals and Microcyn are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

In a City Hard Hit by the Pandemic, Fisher Brothers Complete Indoor Air Quality Projects to Enhance Safety in the Firm's Iconic New York City Buildings

Retrieved on: 
Wednesday, January 27, 2021
Sarbecovirus, Respiratory diseases, Bat virome, Animal diseases, Severe acute respiratory syndrome, Zoonoses

An independent third-party study evaluated the efficacy of RGF's proprietary products with PHI-Cell technology in the inactivation of SARS-CoV-2.

Key Points: 
  • An independent third-party study evaluated the efficacy of RGF's proprietary products with PHI-Cell technology in the inactivation of SARS-CoV-2.
  • The study demonstrated a rate of effectiveness that is greater than 99.9% against the SARS-CoV-2 virus.
  • The testing, performed at the Innovative Bioanalysis Laboratories in Cypress, California, looked at neutralizing the virus within the occupied space in the air and on surfaces.
  • The product(s) and technologies described are not medical devices and are not intended to diagnose, treat, cure, or prevent any disease, virus or illness.

TOMI Environmental Completes Study With University of Virginia Demonstrating Its Disinfection Unit Achieves Kill on SARS CoV-2 Virus in 5 Seconds

Retrieved on: 
Wednesday, January 27, 2021
Sarbecovirus, Safety, Zoonoses, Respiratory diseases, Biological hazards, Bat virome, Severe acute respiratory syndrome, Coronavirus, Medical specialties, Biosafety

There was reduction in the number of SARS CoV-2 PFUs in all exposure methods used to the point where there was no detectable viable coronavirus.

Key Points: 
  • There was reduction in the number of SARS CoV-2 PFUs in all exposure methods used to the point where there was no detectable viable coronavirus.
  • The successful study was conducted at the University of Virginias Biosafety Level 3 facility, which is approved for Select Agent research by the Centers for Disease Control and Prevention.
  • Represented by the SteraMist brand of products, iHP produces a germ-killing aerosol that works like a visual non-caustic gas.
  • We undertake no obligation to update these forward-looking statements after the date of this release.

Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19

Retrieved on: 
Wednesday, January 27, 2021
Coronaviridae, Sarbecovirus, Medicine, Health sciences, Zoonoses, COVID-19 drug development, Bat virome, Bamlanivimab, Coronavirus disease, Coronavirus, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome

Vir and GSK are advancing VIR-7831 as part of their collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2.

Key Points: 
  • Vir and GSK are advancing VIR-7831 as part of their collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2.
  • The safety and efficacy of bamlanivimab is being evaluated with other neutralizing antibodies to provide a possible safeguard against potential viral resistance.
  • Healthcare providers should review the Fact Sheet for information on the authorized use of bamlanivimab and mandatory requirements of the EUA.
  • We are collaborating with Vir Biotechnology to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19.

Adagio Therapeutics Publishes Preclinical Data in Science Demonstrating Best-in-Class Breadth and Potency Against SARS-CoV-2, Including Known Circulating Resistance Variants, and a Range of Pre-Emergent Coronaviruses

Retrieved on: 
Monday, January 25, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Sarbecovirus, Zoonoses, Animal diseases, Respiratory diseases, Bat virome, Severe acute respiratory syndrome, Coronavirus disease, Variants of SARS-CoV-2

The data show that ADG2 effectively binds to and has the potential to protect against common circulating SARS-CoV-2 variants as well as future SARS-related viruses with pandemic potential.

Key Points: 
  • The data show that ADG2 effectively binds to and has the potential to protect against common circulating SARS-CoV-2 variants as well as future SARS-related viruses with pandemic potential.
  • Adagios half-life engineered version of ADG2, called ADG20, could offer protection against COVID-19 for up to a year.
  • ADG2 (the precursor to ADG20) provided complete protection against severe SARS-CoV-2 and SARS-CoV disease in murine models of COVID-19 and SARS, respectively.
  • ADG20 was designed to provide patients and clinicians with an unsurpassed combination of potency, breadth, durable protection (via half-life extension), manufacturability, tolerability, and affordability.

Inhibitory effect on the novel coronavirus (SARS-CoV-2) confirmed through testing of Panasonic's air conditioners with nanoe™ X technology

Retrieved on: 
Thursday, January 21, 2021
Zoonoses, Bat virome, Sarbecovirus, Virology, Medical specialties, Coronaviridae, Novel coronavirus, Severe acute respiratory syndrome, Air conditioning, Coronavir, Middle East respiratory syndrome–related coronavirus, Conditioner

nanoe X is a technology that collects invisible moisture in the air and applies a high voltage to it to produce hydroxyl radicals contained in water.

Key Points: 
  • nanoe X is a technology that collects invisible moisture in the air and applies a high voltage to it to produce hydroxyl radicals contained in water.
  • In these circumstances, Texcell confirmed that nanoe X had a 91.4% inhibitory effect on the novel coronavirus in a space of 6.7m3 in eight hours using an air conditioner with nanoe X.
  • Testing the inhibitory effect of an air conditioner with nanoe X on the novel coronavirus (SARS-CoV-2) in a space of 6.7m3.
  • Note: This verification was designed to generate basic research data on the effects of nanoe X on the novel coronavirus in laboratory conditions different from those found in living spaces.

Air Treatment Solution for Public Transit Approved by EPA to Provide Continuous Protection Against COVID-19

Retrieved on: 
Tuesday, January 19, 2021
Bat virome, Sarbecovirus, Severe acute respiratory syndrome, Coronavirus disease, Antimicrobial, Grignard, Animal diseases, Medical specialties, Infectious diseases

RAHWAY, NJand PLANO, TX, Jan. 19, 2021 /PRNewswire/ -- The U.S. Environmental Protection Agency (EPA) approved a Section 18 Public Health Emergency Exemption for the use of Grignard Pure , an antimicrobial air treatment solution, for intrastate transit and transportation applications.

Key Points: 
  • RAHWAY, NJand PLANO, TX, Jan. 19, 2021 /PRNewswire/ -- The U.S. Environmental Protection Agency (EPA) approved a Section 18 Public Health Emergency Exemption for the use of Grignard Pure , an antimicrobial air treatment solution, for intrastate transit and transportation applications.
  • Administered through Luminator Technology Group 's (Luminator) Renew Air Treatment System , the solution provides continuous protection against SARS-CoV-2, the virus that causes COVID-19.
  • Grignard Pure is expected to kill 98% of SARS-CoV-2 virus particles in the air, where transmission is most likely.
  • When in use, it delivers continuously effective protection of indoor occupied and unoccupied spaces, including transit buses and railcars.

Paragon Genomics NGS Panel Captures New SARS-CoV-2 Mutations

Retrieved on: 
Friday, January 15, 2021
Coronaviridae, Sarbecovirus, Zoonoses, Bat virome, Variants of SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2, Coronavirus disease, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Mutation, Variant of Concern 202012/01

The CleanPlex SARS-CoV-2 FLEX Panel for full viral genome sequencing has been updated to specifically and confidently capture these new emerging mutations of this ever-evolving virus.

Key Points: 
  • The CleanPlex SARS-CoV-2 FLEX Panel for full viral genome sequencing has been updated to specifically and confidently capture these new emerging mutations of this ever-evolving virus.
  • The FLEX panel assay design covers the critical N501Y mutation and 69/70 deletion along with other mutations specific to these new variants.
  • "The SARS-CoV-2 FLEX panel is built upon the original SARS-CoV-2 panel and contains additional critical design elements for detecting new mutations and variants over time.
  • For more information on Paragon Genomics' CleanPlex SARS-CoV-2 Flex panel and other COVID-19 related products, check out https://www.paragongenomics.com/ .

SML Genetree Receives FDA Emergency Use Authorization for Ezplex SARS-CoV-2 G Real-Time PCR Kit with Specimen Pooling Capability

Retrieved on: 
Thursday, January 14, 2021
Branches of biology, Sarbecovirus, Medicine, Clinical medicine, Bat virome, Biotechnology, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, GeneTree, Molecular diagnostics

"By providing a pooling protocol, we can assist laboratories in meeting the demand for accurate, high volume molecular test results," said SML Genetree's CEO, Mr. Jihoon Ahn.

Key Points: 
  • "By providing a pooling protocol, we can assist laboratories in meeting the demand for accurate, high volume molecular test results," said SML Genetree's CEO, Mr. Jihoon Ahn.
  • The Ezplex SARS-CoV-2 G Kit is designed to provide sensitive and accurate results by detecting two different regions of the SARS-CoV-2 virus: the RdRP and N genes.
  • SML Genetree is recognized as a leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics in South Korea.
  • SML Genetree is an affiliate of Samkwang Medical Laboratories (SML), one of the largest diagnostic commercial labs in Korea since 1985.

SML Genetree Receives FDA Emergency Use Authorization for Ezplex SARS-CoV-2 G Real-Time PCR Kit with Specimen Pooling Capability

Retrieved on: 
Thursday, January 14, 2021
Branches of biology, Sarbecovirus, Medicine, Clinical medicine, Bat virome, Biotechnology, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, GeneTree, Molecular diagnostics

"By providing a pooling protocol, we can assist laboratories in meeting the demand for accurate, high volume molecular test results," said SML Genetree's CEO, Mr. Jihoon Ahn.

Key Points: 
  • "By providing a pooling protocol, we can assist laboratories in meeting the demand for accurate, high volume molecular test results," said SML Genetree's CEO, Mr. Jihoon Ahn.
  • The Ezplex SARS-CoV-2 G Kit is designed to provide sensitive and accurate results by detecting two different regions of the SARS-CoV-2 virus: the RdRP and N genes.
  • SML Genetree is recognized as a leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics in South Korea.
  • SML Genetree is an affiliate of Samkwang Medical Laboratories (SML), one of the largest diagnostic commercial labs in Korea since 1985.